GlassScriptPhysician profile
Megan N Thomas
NPI 1235480872
$5,062.54
in general payments reported to CMS, 2019-2025
25 companies · $769 in 2025
The $769 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,739 · 2022: $672 · 2023: $1,072 · 2024: $810 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.54 |
| Education | $318.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,412.39 | 2021-2022 | |
| Janssen Biotech, INC. | $585.09 | 2022-2025 | Tremfya |
| Abbvie INC. | $494.03 | 2021-2025 | |
| Dermavant Sciences, INC. | $280.10 | 2023-2024 | Vtama |
| Genzyme Corporation | $269.78 | 2023 | |
| Novartis Pharmaceuticals Corporation | $264.37 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $186.91 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Botanix Sb INC | $179.35 | 2025 | Sofdra |
| Incyte Corporation | $165.22 | 2021-2022 | |
| Merz North America, INC. | $151.09 | 2024 | |
| Verrica Pharmaceuticals INC. | $148.90 | 2023 | Ycanth |
| Lilly USA, LLC | $137.95 | 2021-2025 | Taltz, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.69 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $86.04 | 2021-2023 | Ilumya |
| Bayer Healthcare Pharmaceuticals INC. | $85.57 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $80.34 | 2021-2025 | Aklief |
| Pfizer INC. | $75.03 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $74.34 | 2021 | |
| Almirall LLC | $58.98 | 2023-2025 | Klisyri, Seysara |
| Ucb, INC. | $41.57 | 2021 | |
| Journey Medical Corporation | $38.47 | 2023-2025 | |
| Leo Pharma INC. | $38.27 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.67 | 2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $30.25 | 2021 | |
| Organon LLC | $18.14 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.